Evonik Closes Acquisition of Lactel Absorbable Polymers Product Line
Evonik has closed its acquisition of the Lactel Absorbable Polymers product line from DURECT Corporation on Dec. 31, 2020.
In a Jan 5, 2021 press release, Evonik reported the closing of its acquisition of the Lactel Absorbable Polymers product line from DURECT Corporation on Dec. 31, 2020, marking a significant step in the company’s growth agenda.
“The acquisition of the Lactel business will strengthen both our innovation growth field Healthcare Solutions and Evonik’s position as a globally leading CDMO [contract development and manufacturing organization] for drug delivery solutions,” said Johann-Caspar Gammelin, head of the Nutrition & Care Division of Evonik, in the press release.
“The integration of the Lactel business into Evonik’s market-leading portfolio of functional excipients, biomaterials, and integrated CDMO services will strengthen our position as a preferred development partner and solutions provider,” added Thomas Riermeier, head of the Health Care business line, in the press release. “By welcoming Lactel and members of their team into the Evonik family, we look forward to providing customers with even greater platform versatility as well as other value-adding services.”
All employees of DURECT associated with the Lactel business in Birmingham, AL, have agreed to join Evonik in similar roles.
Source: Evonik
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Drug Shortages and Complying with FDA’s 21 CFR 211.110 Guidance
April 2nd 2025Susan J. Schniepp, distinguished fellow at Regulatory Compliance Associates, and Rona LeBlanc-Rivera, PhD, principal consultant, Regulatory Affairs at Regulatory Compliance Associates, answer some questions about FDA’s January 2025 21 CFR 211.110 guidance document.
INTERPHEX 2025: Use of Walk-In Chambers for Bio/Pharma Development and Manufacturing
April 2nd 2025Sitting down with the PharmTech Group at INTERPHEX 2025, Christopher Murphy, director of Global Business Development and Service Customer Support at Environmental Specialties, discusses the design and critical role of walk-in chambers in the bio/pharmaceutical industry.
